Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

04.10.2023 - CAMBRIDGE, Mass. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) - Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients with ... Seite 1

Related Keywords

Helena Yu ,Memorial Sloan Kettering Cancer Center ,Preliminary Dose Escalation ,Associate Attending Physician ,Memorial Sloan Kettering Cancer ,Preclinical Efficacy ,Targeting Oncogenic ,Upstream Driver ,Elizabeth Buck ,Chief Scientific Officer ,Black Diamond ,Poster Session ,